- Home
- HSHP vs DMAC Comparison
HSHP vs DMAC Comparison
Compare HSHP & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSHP
- DMAC
- Stock Information
- Founded
- HSHP 2021
- DMAC 2000
- Country
- HSHP Bermuda
- DMAC United States
- Employees
- HSHP N/A
- DMAC N/A
- Industry
- HSHP
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- HSHP
- DMAC Health Care
- Exchange
- HSHP Nasdaq
- DMAC Nasdaq
- Market Cap
- HSHP 268.6M
- DMAC 310.1M
- IPO Year
- HSHP 2023
- DMAC N/A
- Fundamental
- Price
- HSHP $7.92
- DMAC $5.37
- Analyst Decision
- HSHP
- DMAC Strong Buy
- Analyst Count
- HSHP 0
- DMAC 3
- Target Price
- HSHP N/A
- DMAC $12.33
- AVG Volume (30 Days)
- HSHP 98.7K
- DMAC 327.4K
- Earning Date
- HSHP 08-08-2025
- DMAC 08-12-2025
- Dividend Yield
- HSHP 5.33%
- DMAC N/A
- EPS Growth
- HSHP N/A
- DMAC N/A
- EPS
- HSHP 0.14
- DMAC N/A
- Revenue
- HSHP $120,680,000.00
- DMAC N/A
- Revenue This Year
- HSHP $7.10
- DMAC N/A
- Revenue Next Year
- HSHP $26.34
- DMAC N/A
- P/E Ratio
- HSHP $58.38
- DMAC N/A
- Revenue Growth
- HSHP 44.77
- DMAC N/A
- 52 Week Low
- HSHP $4.29
- DMAC $3.19
- 52 Week High
- HSHP $8.74
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- HSHP 65.98
- DMAC 50.22
- Support Level
- HSHP $7.49
- DMAC $5.14
- Resistance Level
- HSHP $7.71
- DMAC $6.16
- Average True Range (ATR)
- HSHP 0.14
- DMAC 0.30
- MACD
- HSHP 0.00
- DMAC -0.12
- Stochastic Oscillator
- HSHP 94.12
- DMAC 22.12
About HSHP Himalaya Shipping Ltd.
Himalaya Shipping Ltd is an independent dry bulk company that focuses on owning and operating its Newcastlemax dry bulk carriers.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.